CAR-γδ T Cells Targeting Claudin18.2 Show Superior Cytotoxicity Against Solid Tumor Compared to Traditional CAR-αβ T Cells
Our results demonstrate that universal CAR-CLDN18.2-γδ T cell is promising for the treatment of CLDN18.2-positive solid tumor and provide insights for the development of more universal CAR-γδ T-cell strategies for tumor immunotherapy.
Authors
- Shuaiqi Wang
- Y. P. Xu (ORCID: https://orcid.org/0000-0002-8476-9217)
- Yueqi Zhao (ORCID: https://orcid.org/0000-0003-1867-8891)
- Jingyi Han (ORCID: https://orcid.org/0000-0002-3765-2788)
- Menghua Cai
- Wanfu Qiao (ORCID: https://orcid.org/0000-0003-2672-7622)
- Hui Chen (ORCID: https://orcid.org/0009-0004-3980-1005)
- Jianmin Zhang (ORCID: https://orcid.org/0000-0003-4765-0812)
- Yinghui Li (ORCID: https://orcid.org/0000-0002-9023-9466)
- Xu Yi (ORCID: https://orcid.org/0000-0001-7802-6743)
- Yu Hu (ORCID: https://orcid.org/0009-0003-7254-3477)
- Wei He (ORCID: https://orcid.org/0000-0003-1185-1014)
- Mingyang Lu
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Cell Technology (China) (HK)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-17
- DOI
- https://doi.org/10.3390/cancers17060998
- Citations
- 6
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine